FDA finds no indication that CBD has abuse potential or significant risk to public health
On October 1, 2018, a Food and Drug Administration (“FDA”) communication was publicly released on the subject of cannabidiol (“CBD”).
After a thorough scientific review and analysis, the FDA argues:
“There is little indication that CBD has abuse potential or presents a significant risk to the public health.”
“No evidence for a classic drug withdrawal syndrome for CBD, and no evidence that CBD causes physical or psychic dependence.”
“CBD does not appear to have abuse potential under the CSA.”
“There is no signal for the development of substance use disorder in individuals consuming CBD-containing products.”
“It is unlikely that CBD would act as an immediate precursor to THC for abuse purposes.”
The FDA communication makes clear that the federal agency with primary jurisdiction over the health and welfare of the American public has taken the formal position that CBD should not be treated as a controlled substance, which is expected to be removed from the controlled substance act once the 2018 Farm Bill Act is signed in to law by President Trump.
Following in the foot steps of the World Health Organization, which in August recommended that CBD not be scheduled under international drug conventions, the FDA, in this announcement signals their stance on the safety and efficacy of hemp CBD .